COMP <GO>
JBIO vs OBX // EV/EBITDA & P/E VALUATION
Jade Biosciences Inc. (NASDAQ) VS. Obsidian Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: JBIO 1
— OBX 2
■ METRIC PARITY
LAST: $14.24 (-2.40%) • MKT CAP: $905.6M
valuation
—
LAST: $14.52 (-0.48%) • MKT CAP: $896.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JBIO VS. OBX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JBIO | OBX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -10.48% | -10.09% | -0.39 | OBX | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 26.00 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.4 | 55.6 | -15.17 | OBX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $905.6M | $896.9M | $8.7M | JBIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JBIO REV | OBX REV | JBIO GROSS % | OBX GROSS % | JBIO FCF | OBX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$94.9M | -$90.5M |
| FY 2024 | $0 | $0 | — | — | -$71.2M | -$75.8M |
| FY 2023 | $0 | — | — | — | -$56.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JBIO // BETA —
OBX // BETA —